41 results
F-3
CANF
Can-Fite Biopharma Ltd
1 Sep 23
Shelf registration (foreign)
4:15pm
be highly toxic, expensive and not always effective.
Like Piclidenoson, Namodenoson has a good safety profile, is orally administered and has a low cost
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
31 Aug 23
Report of Foreign Private Issuer
7:12am
the competition in psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
25 Aug 22
Report of Foreign Private Issuer
7:16am
the competition in psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive
424B5
pq5tjngpfdj nt0
8 Jul 20
Prospectus supplement for primary offering
10:42am
424B5
kz4wdn 9m
12 Jun 20
Prospectus supplement for primary offering
8:30am
424B3
tnuov73o638po54l722
7 Apr 20
Prospectus supplement
4:36pm
POS AM
hjnf svqo70we
6 Apr 20
Prospectus update (post-effective amendment)
3:16pm
F-1
yr5o1 vwaf6dnelv22
27 Mar 20
Registration statement (foreign)
4:44pm
POS AM
i56 v58nzqj2gqxch
27 Mar 20
Prospectus update (post-effective amendment)
4:27pm
424B4
8k2p 3iyk626rs2
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
lz6s pjiz0cf4
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
y2wqjm
24 Jan 20
Registration statement (foreign)
4:40pm
424B5
ljym7 7ydru
22 May 19
Prospectus supplement for primary offering
9:20am
424B5
v757yy
4 Apr 19
Prospectus supplement for primary offering
9:19am
20-F/A
c1e jd7qx
2 Apr 19
Annual report (foreign) (amended)
6:52am